Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
Luxturna, a one-time treatment for a rare inherited form of blindness, would not be cost-effective at the $1m price level that has been suggested as a possibility, based on ICER's thresholds. But the small patient population would keep it from triggering ICER's US budget spending threshold.
Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.
The company plans to file an NDA with FDA in the first half of 2018 for an intravenous formulation of brexanolone, which could be the first treatment specifically for postpartum depression.
Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.
Management did not disclose the pricing strategy for the gene therapy for blindness during its third quarter financial update, but did confirm that the value of the therapy is in excess of $1m per patient.
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.